Exosomes as Carriers of Alzheimer's Amyloid-ß
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The intracerebral level of the aggregation-prone peptide, amyloid-ß (Aß), is constantly maintained by multiple clearance mechanisms, including several degradation enzymes, and brain efflux. Disruption of the clearance machinery and the resultant Aß accumulation gives rise to neurotoxic assemblies, leading to the pathogenesis of Alzheimer's disease (AD). In addition to the classic mechanisms of Aß clearance, the protein may be processed by secreted vesicles, although this possibility has not been extensively investigated. We showed that neuronal exosomes, a subtype of extracellular nanovesicles, enwrap, or trap Aß and transport it into microglia for degradation. Here, we review Aß sequestration and elimination by exosomes, and discuss how this clearance machinery might contribute to AD pathogenesis and how it might be exploited for effective AD therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · cited 1×
“In sporadic AD, a common form of AD, the rate of Aß elimination in the brain is reduced (Mawuenyega et al., 2010).”
BackgroundDepletion of microglia and inhibition of exosome synthesis halt tau propagation
Asai, H., Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., Wolozin, B., Butovsky, O., Kügler, S., & Ikezu, T. (2015) · Nature Neuroscience · doi:10.1038/nn.4132 · Cited by 1,591 · cited 1×
“The exosomes derived from Aßstimulated astrocytes and aggregated tau-treated microglia are involved in Aß aggregation and tau interneuronal propagation, respectively (Asai et al., 2015; Dinkins et al., 2016; Xiao et al., 2017).”
BackgroundCellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M. (2009) · Nature · doi:10.1038/nature07761 · Cited by 1,560
Zhuang, X., Xiang, X., Grizzle, W., Sun, D., Zhang, S., Axtell, R. C., Ju, S., Mu, J., Zhang, L., Steinman, L., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.164 · Cited by 1,356
Alzheimer’s disease β-amyloid peptides are released in association with exosomes
Rajendran, L., Honsho, M., Zahn, T. R., Keller, P., Geiger, K. D., Verkade, P., & Simons, K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603838103 · Cited by 1,343
Identification of Tim4 as a phosphatidylserine receptor
Miyanishi, M., Tada, K., Koike, M., Uchiyama, Y., Kitamura, T., & Nagata, S. (2007) · Nature · doi:10.1038/nature06307 · Cited by 1,180 · cited 1×
“Notably, exosomal PS is localized in the outer leaflet of the surface membranes, as well as apoptotic cells, and can be recognized by the microglial PS receptor (Miyanishi et al., 2007).”
BackgroundFiandaca, M. S., Kapogiannis, D., Mapstone, M., Boxer, A., Eitan, E., Schwartz, J. B., Abner, E. L., Petersen, R. C., Federoff, H. J., Miller, B. L., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.008 · Cited by 959
Selective transfer of exosomes from oligodendrocytes to microglia by macropinocytosis
Fitzner, D., Schnaars, M., van Rossum, D., Krishnamoorthy, G., Dibaj, P., Bakhti, M., Regen, T., Hanisch, U.-K., & Simons, M. (2011) · Journal of Cell Science · doi:10.1242/jcs.074088 · Cited by 866
Engineering hybrid exosomes by membrane fusion with liposomes
Sato, Y. T., Umezaki, K., Sawada, S., Mukai, S.-A., Sasaki, Y., Harada, N., Shiku, H., & Akiyoshi, K. (2016) · Scientific Reports · doi:10.1038/srep21933 · Cited by 744 · cited 1×
“As nanotechnological approaches, these functional exosomes or exosome-like liposomes, or even fusion vesicles of both types (Ashraf et al., 2015; Sato et al., 2016; Ansari et al., 2017) that restore brain capacity, might be a valuable tools for AD therapy.”
Background
Cited by
Bidirectional Microglia–Neuron Communication in Health and Disease
Szepesi, Z., Manouchehrian, O., Bachiller, S., & Deierborg, T. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00323 · Cited by 459
“The administration of neuronal exosomes into the brain of APP transgenic mice results in a decreased amyloid deposition and neuronal exosomes can effectively ameliorates AD pathology (Yuyama et al., 2015; Yuyama and Igarashi, 2016, 2017).”
BackgroundBuratta, S., Tancini, B., Sagini, K., Delo, F., Chiaradia, E., Urbanelli, L., & Emiliani, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072576 · Cited by 446
Men, Y., Yelick, J., Jin, S., Tian, Y., Chiang, M. S. R., Higashimori, H., Brown, E., Jarvis, R., & Yang, Y. (2019) · Nature Communications · doi:10.1038/s41467-019-11534-w · Cited by 357
Yamashita, T., Takahashi, Y., & Takakura, Y. (2018) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b18-00133 · Cited by 306
Challenges and hopes for Alzheimer’s disease
Tatulian, S. A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.01.016 · Cited by 291
Metadata
- Authors
- Yuyama, K., & Igarashi, Y.
- Venue
- Frontiers in Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2017-04-25
- Volume
- 11
- Pages
- 229-229
- ISSN
- 1662-453X (ISSN-L)
- OpenAlex
- W2609601076
- Cited by
- 114
- References
- 17
- FWCI
- 8.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exosomes as Carriers of Alzheimer's Amyloid-ß. https://app.cochat.ai/papers/10.3389/fnins.2017.00229
- The paper
- Yuyama, K., & Igarashi, Y. (2017). Exosomes as Carriers of Alzheimer's Amyloid-ß. Frontiers in Neuroscience. https://doi.org/10.3389/fnins.2017.00229
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.